Literature DB >> 29959082

Do Selected Blood Inflammatory Markers Combined with Radiological Features Predict Proliferation Index in Glioma Patients?

Yinlun Weng1, Xueyuan Zhang2, Jingjing Han3, Leping Ouyang1, Mingqin Liang1, Zhongsong Shi1, Anmin Liu1, Wangqing Cai4.   

Abstract

BACKGROUND: The tumor microenvironment is partially characterized by a state of chronic inflammation, and radiologic features are related to the tumor's biological behavior. This study was conducted to explore whether peripheral blood inflammatory markers combined with radiologic features could predict proliferation potency.
METHODS: This study retrospectively reviewed 183 patients with a primary diagnosis of glioma. Clinical characteristics, preoperative peripheral full blood count data, and brain magnetic resonance imaging findings were reviewed to analyze the expression of inflammatory markers neutrophil lymphocyte ratio (NLR), monocyte lymphocyte ratio, and platelet lymphocyte ratio (PLR), as well as radiologic features such as location, peritumor edema, and contrast enhancement. Immunohistochemical staining was performed to determine the proliferation index (i.e., expression of Ki-67). Receiver operating characteristic curves for cutoff value, various bivariate tests, and binary logistic regression analyses were applied.
RESULTS: Proliferation index was highly associated with tumor grade, showing a gradually increasing tendency. A Ki-67 cutoff value >9% predicted high-grade glioma (HGG). Mean NLR and PLR were significantly higher in the HGG group compared with the low-grade glioma group (NLR: 3.11 ± 0.59 vs. 4.27 ± 1.13; PLR: 133.07 ± 13.17 vs. 161.51 ± 38.99; P < 0.01 for both). Contrast enhancement was more likely in the HGG group, but there was no significant between-group difference in peritumor edema. Logistic regression analysis identified the following risk factors for prediction of proliferation potency: age, Karnofsky Performance Score, NLR, PLR, and contrast enhancement. However, age >43 years, NLR >3.68, and positive contrast enhancement independently predicted a higher proliferation rate.
CONCLUSIONS: NLR and contrast enhancement were positively correlated with the proliferation potency of gliomas.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical characteristics; Glioma; Inflammation marker; Proliferation potency; Radiologic feature

Mesh:

Substances:

Year:  2018        PMID: 29959082     DOI: 10.1016/j.wneu.2018.06.142

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?

Authors:  Jing Guo; Jialiang Ren; Junkang Shen; Rui Cheng; Yexin He
Journal:  Diagn Interv Radiol       Date:  2021-05       Impact factor: 2.630

2.  Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.

Authors:  Qing Zhang; Junwen Zhang; Yifu Tian; Guidong Zhu; Sisi Liu; Fusheng Liu
Journal:  Cell Biosci       Date:  2020-10-27       Impact factor: 7.133

3.  Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma.

Authors:  Guangda Xu; Chengxue Li; Yanguo Wang; Jinan Ma; Junchen Zhang
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

4.  Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta-Analysis.

Authors:  Da-Peng Wang; Kai Kang; Qi Lin; Jian Hai
Journal:  Clin Transl Sci       Date:  2019-10-30       Impact factor: 4.689

5.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.